Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience.
Head and neck cancer
Immunotherapy
Nivolumab
Radiotherapy
Re-irradiation
SBRT
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
17
11
2021
revised:
24
11
2021
accepted:
27
11
2021
pubmed:
10
12
2021
medline:
12
4
2022
entrez:
9
12
2021
Statut:
ppublish
Résumé
In metastatic and recurrent head and neck cancer (M/R HN-SCC), the median survival is less than a year and locoregional recurrence is the main cause of death. Our aim was to evaluate the results of concurrent stereotactic body radiotherapy (SBRT) and immunotherapy (ICI) in these patients. Fifteen patients diagnosed with M/R HN-SCC were evaluated retrospectively. All patients received SBRT (3x8 Gy) to all recurrent and metastatic foci with concurrent ICI. Six months overall survival (OS) rates and progression-free survival (PFS) rates were 93% and 86%, respectively. Local control (LC) rate in the site of SBRT was 96%. Higher survival and LC rates were achieved with lower doses of radiotherapy with the synergistic effect of SBRT and ICI. Concurrent ICI and SBRT was feasible with excellent LC.
Identifiants
pubmed: 34883400
pii: S1368-8375(21)00765-X
doi: 10.1016/j.oraloncology.2021.105658
pii:
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
105658Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.